Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03295071 · ClinicalTrials.gov registry record
REALITY LHON Registry
A clinical trial, sponsored by GenSight Biologics.
- Completed
- Registry status
- 44
- Enrollment target
NCT03295071: Completed study, sponsored by GenSight Biologics.
NCT03295071 is a clinical trial that has completed, run by GenSight Biologics. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03295071 has completed, sponsored by GenSight Biologics.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
Primary Outcome
Visual function will include visual examination data from medical records.
Interventions
- OTHER Patient-reported outcomes (PROs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2020-07-01 |
What the finished NCT03295071 record still lists
NCT03295071 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Patient-reported outcomes (PROs) is the first listed.
NCT03295071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03295071 about?
NCT03295071 is a clinical study titled "REALITY LHON Registry". This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
What is the current status of trial NCT03295071?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2018-01-03. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT03295071?
The interventions under investigation include: Patient-reported outcomes (PROs) (OTHER).
Who is sponsoring clinical trial NCT03295071?
This trial is sponsored by GenSight Biologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI